Indivior Pharmaceuticals, Inc. INDV Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Indivior Pharmaceuticals, Inc. 's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Indivior Pharmaceuticals, Inc. 's accounts payable and other current liabilities (note 11)?
- Indivior Pharmaceuticals, Inc. (INDV) reported accounts payable and other current liabilities (note 11) of $178M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc. 's accounts payable and other current liabilities (note 11) changed year-over-year?
- Indivior Pharmaceuticals, Inc. 's accounts payable and other current liabilities (note 11) decreased by 2.7% year-over-year, from $183M to $178M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc. 's accounts payable and other current liabilities (note 11)?
- Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's accounts payable and other current liabilities (note 11) has grown at a 13.2% compound annual growth rate (CAGR), from $195M to $250M.